MoldCo

About MoldCo

MoldCo is a telehealth company addressing chronic health issues arising from mold and biotoxin exposure. The company was established in 2023 and is headquartered in Boston, Massachusetts. Its creation was spurred by the personal health struggles of its founder and CEO, Ariana Thacker. A former venture capital investor and chemical engineer, Thacker experienced a series of debilitating, mysterious symptoms while running her own VC firm. After discovering the cause was toxic mold in her Miami apartment, she delved into the research of mold-related illnesses and was inspired to create a more accessible solution for others.

The company operates as a healthcare technology platform connecting patients with a network of independent, third-party licensed clinicians who specialize in mold-related conditions, particularly Chronic Inflammatory Response Syndrome (CIRS). MoldCo's business model centers on providing patients with access to specialized lab tests, personalized care plans from mold-certified clinicians, and evidence-based treatments delivered directly to their homes. The approach is guided by the Shoemaker Protocol, a treatment framework developed over three decades with experience from over 30,000 patients. Revenue is generated through technology and service fees, with transparent pricing for its programs that bundle consultations, lab testing access, and prescribed treatments.

The service begins with a detailed online intake to assess symptoms and potential exposures, after which a provider designs a personalized treatment protocol. This telehealth model aims to overcome common barriers in traditional healthcare, such as the lack of recognition for mold-related illness, limited specialist availability, and high costs. Following a public launch, the company secured $3 million in pre-seed funding to support a nationwide expansion planned for 2025. It is currently accepting patients in select states.